[go: up one dir, main page]

UA96622C2 - Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования - Google Patents

Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования

Info

Publication number
UA96622C2
UA96622C2 UAA200909671A UAA200909671A UA96622C2 UA 96622 C2 UA96622 C2 UA 96622C2 UA A200909671 A UAA200909671 A UA A200909671A UA A200909671 A UAA200909671 A UA A200909671A UA 96622 C2 UA96622 C2 UA 96622C2
Authority
UA
Ukraine
Prior art keywords
aliskiren
solvent
solid dosage
granulation process
dosage forms
Prior art date
Application number
UAA200909671A
Other languages
English (en)
Ukrainian (uk)
Inventor
Франц Врецер
Вида Скрабанйа
Наталия Зайц
Урска Гойяк
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of UA96622C2 publication Critical patent/UA96622C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к фармацевтическому препарату, который содержит как активный ингредиент алискирен или его фармацевтически приемлемую соль, где указанный фармацевтический препарат содержится в твердой лекарственной форме, пригодной для перорального введения, на основе гранулята, полученного способом высокотемпературного гранулирования из расплава в отсутствии растворителя, и к способу производства фармацевтического препарата.
UAA200909671A 2007-03-23 2008-03-20 Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования UA96622C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07006055A EP1972335A1 (en) 2007-03-23 2007-03-23 Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
UA96622C2 true UA96622C2 (ru) 2011-11-25

Family

ID=38006908

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200909671A UA96622C2 (ru) 2007-03-23 2008-03-20 Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования

Country Status (5)

Country Link
US (1) US20100143460A1 (ru)
EP (2) EP1972335A1 (ru)
EA (1) EA020331B1 (ru)
UA (1) UA96622C2 (ru)
WO (1) WO2008116601A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2483718C2 (ru) * 2007-09-28 2013-06-10 Новартис Аг Галеновые композиции алискирена
JP2011522829A (ja) * 2008-06-06 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド 固体状のアリスキレン遊離塩基
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2393489B1 (en) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN106620644B (zh) * 2016-12-13 2021-05-25 杭州新诺华医药有限公司 一种稳定的培哚普利吲达帕胺片及制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
WO2003097098A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
EP1782859A3 (en) * 2003-04-11 2009-09-30 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
PE20060362A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de oxazol como moduladores de ppar
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
MX2007004020A (es) * 2004-10-08 2007-05-24 Novartis Ag Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
BRPI0609915A2 (pt) * 2005-04-27 2010-05-25 Novartis Ag métodos para tratar aterosclerose
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt

Also Published As

Publication number Publication date
WO2008116601A4 (en) 2009-09-24
EA200901146A1 (ru) 2009-12-30
EA020331B1 (ru) 2014-10-30
EP1972335A1 (en) 2008-09-24
WO2008116601A2 (en) 2008-10-02
WO2008116601A3 (en) 2009-07-23
EP2136789A2 (en) 2009-12-30
US20100143460A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
NZ605469A (en) Nalbuphine-based formulations and uses thereof
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
IL197393A (en) History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
TN2010000135A1 (en) Galenical formulations of organic compounds
PH12014500853A1 (en) Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof
WO2008023016A3 (en) Galenic formulations of aliskiren
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
HRP20160327T1 (hr) Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom
HK1208222A1 (en) Modified release formulations for oprozomib
EP2316420A8 (en) Method to reduce pain
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2005107721A3 (en) Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2009040373A3 (en) Galenical formulations of aliskiren
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
PL379192A1 (pl) Tetrahydrat soli kwasu benzochinolizyno-2-karboksylowego z argininą
WO2005115346A3 (en) Pharmaceutical composition containing risperidone